Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue SUPPL. 1, 1996, Pages

  Meyer, Urs A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Cytochrome P450; Interactions; Lansoprazole; Omeprazole; Pantoprazole; Sulfotransferase

Indexed keywords

CAFFEINE; CARBAMAZEPINE; CYTOCHROME P450; DIAZEPAM; LANSOPRAZOLE; OMEPRAZOLE; OXYGENASE; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; THEOPHYLLINE;

ARTICLE; DRUG METABOLISM; GENETIC POLYMORPHISM; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PEPTIC ULCER; POLYMORPHISM, GENETIC; STRUCTURE-ACTIVITY RELATIONSHIP; SULFOXIDES;

EID: 0029803802     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199610001-00005     Document Type: Article

References (38)

1. Wilde MI, McTavis D: Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drug 1994, 48:91-132.
2. Delhotal Landes B, Petite JP, Flouvat B: Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995, 28:458-470.
3. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E: Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995, 9:363-378.
4. Kromer W: Similarities and differences in the properties of substituted benzimidazoles a comparison between pantoprazole and related compounds. Digestion 1995, 56:443-454.
5. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue G, Joyeux H, et al.: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995, 47:410-418.
6. Sohn D-R, Kwon J-T, Kim H-K: Influence of S-mephenytoin phenotype on the lansoprazole metabolism [abstract]. Clin Pharmacol Ther 1996, 59:A137.
7. Andersson T, Miners JO, Veronese ME, et al.: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993, 36:521-530.
8. Andersson T, Miners JO, Veronese ME, Birkett DJ: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994, 37:597-604.
9. Meyer UA: Cytochrome P450 in human drug metabolism: how much is predictable? In Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research. Edited by Waterman MR, Hildebrand M. Berlin: Springer Verlag; 1994:43-56.
10. Guengerich FP: Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd edn. Edited by de Montellano O. London: Plenum Press; 1995:473-535.
11. Meyer UA: The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 1994, 46:409-415.
12. De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994, 269:15419-15422.
13. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism [in Japanese]. Mol Pharmacol 1994, 46:594-598.
14. Andersson T, Regardh C-G, Lou Y-Ch, Zhang Y, Dahl M-L, Bertilsson L: Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990, 12:415-146.
15. Andersson T, Regårdh C-G, Lou Y-Ch, Zhang Y, Dahl M-L, Bertilsson L: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992, 2:25-31.
16. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T: Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993, 266:52-59.
17. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al.: The hydroxylation of omeprazole correlates with S-mephenytom metabolism: a population study. Clin Pharmacother Ther 1995, 57:662-669.
18. Sohn D-R, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 1992, 262:1195-1202.
19. Chang M, Tybring G, Dahl M-L, Götharson E, Sagar M, Seensalu R, Bertilsson L: Interphenotype differences in disposition and effect on gastrin levels of omeprazole: suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995, 39:511-518.
20. Ishizaki T, Sohn D-R, Kobayashi K, Chiba K, Lee KH, Shin SG, et al.: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994, 16:214-215.
21. Price Evans DA, Krahn P, Narayanan N: The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995, 5:64-71.
22. Caraco MD, Lagerstrom PO, Wood AJJ: Ethnic and genetic determinants of omeprazole disposition and effect [abstract]. Clin Pharmacol Ther 1996, 59:A216.
23. Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel, Maurel P: Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990, 99:737-747.
24. McDonnell WM, Scheiman JM, Traber PG: Induction of cytochrome P4501A genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 1992, 103:1509-1516.
25. Buchthal J, Grund KE, Buchmann A, Schrenk D, Beaune P, Bock KW: Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa. Eur J Clin Pharmacol 1995, 47:431-435.
26. Rost KL, Roots I: Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994, 55:402-411.
27. Rost KL, Brösicke H, Heinemeyer G, Roots I: Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 1994, 20:1204-1212.
28. Kokufu T, Ihara N, Sugioka N, et al.: Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995, 48:391-395.
29. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L, et al.: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994, 269:384-392.
30. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, et al.: Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996, 34:243-262.
31. Hartmann M, Bliesath H, Zech K, Koch H, Steinijans VW, Wurst W, et al.: Pantoprazole does not influence CYP1A2 activity in man [abstract]. Gastroenterology 1995, 108 (suppl 4):A109.
32. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P: Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990, 47:79-65.
33. Caraco Y, Tateishi T, Wood AJJ: Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995, 58:62-72.
34. Lefebvre RA, Flouvat B, Karolac-Tamisier S, Moerman E, van Ganse E: Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992, 52:458-463.
35. Gugler R, Hartmann M, Rudi J, Brod I, Steinijans VW, Bliesath H, et al.: Lack of pharmacokinetic interaction of pantoprazole with diazepam in man [abstract]. Br J Clin Pharmacol 1996, 42:249-252.
36. Gugler R, Jensen JC: Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985, 89:1235-1241.
37. Naidu MUR, Shobha JC, Dixit VK, Kumar A, Kumar TR, Sckhar KR, et al.: Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest 1994, 7:8-12.
38. Tucker GT: The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994, 8:33-38.